Boyang Yu Selected Research

ruscogenin

3/2022	Ruscogenin Alleviates Myocardial Ischemia-Induced Ferroptosis through the Activation of BCAT1/BCAT2.
1/2022	Ruscogenin Alleviates Deep Venous Thrombosis and Pulmonary Embolism Induced by Inferior Vena Cava Stenosis Inhibiting MEK/ERK/Egr-1/TF Signaling Pathway in Mice.
1/2021	Mechanisms dissection of the combination GRS derived from ShengMai preparations for the treatment of myocardial ischemia/reperfusion injury.
1/2020	The Traditional Chinese Medicine Compound, GRS, Alleviates Blood-Brain Barrier Dysfunction.
1/2018	DT-13 ameliorates TNF-α-induced nitric oxide production in the endothelium in vivo and in vitro.
1/2017	DT-13 Ameliorates TNF-α-Induced Vascular Endothelial Hyperpermeability via Non-Muscle Myosin IIA and the Src/PI3K/Akt Signaling Pathway.
8/2016	Ruscogenin Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP/NLRP3 Inflammasome Activation and the MAPK Pathway.
1/2015	The saponin DT-13 attenuates tumor necrosis factor-α-induced vascular inflammation associated with Src/NF-кB/MAPK pathway modulation.
8/2013	Ruscogenin reduces cerebral ischemic injury via NF-κB-mediated inflammatory pathway in the mouse model of experimental stroke.
1/2012	Ruscogenin inhibits lipopolysaccharide-induced acute lung injury in mice: involvement of tissue factor, inducible NO synthase and nuclear factor (NF)-κB.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Boyang Yu Research Topics

Disease

13	Inflammation (Inflammations) 01/2022 - 07/2005
12	Brain Ischemia (Cerebral Ischemia) 01/2022 - 06/2008
12	Neoplasms (Cancer) 01/2020 - 11/2010
9	Cardiovascular Diseases (Cardiovascular Disease) 03/2022 - 03/2011
9	Reperfusion Injury 12/2021 - 06/2008
8	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2022 - 08/2013
7	Myocardial Ischemia (Ischemic Heart Diseases) 03/2022 - 11/2016
7	Infarction (Infarctions) 01/2022 - 08/2013
7	Thrombosis (Thrombus) 02/2020 - 06/2006
6	Acute Lung Injury 01/2022 - 01/2012
6	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2010
6	Breast Neoplasms (Breast Cancer) 01/2021 - 12/2009
6	Ischemia 11/2018 - 03/2005
4	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022 - 09/2005
4	Heart Failure 05/2019 - 05/2016
4	Edema (Dropsy) 08/2016 - 07/2005
3	Hypersensitivity (Allergy) 01/2022 - 01/2018
3	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2022 - 01/2016
3	Pheochromocytoma 01/2022 - 01/2016
3	type 2C Congenital disorder of glycosylation 01/2022 - 01/2017
3	Myocardial Infarction 01/2021 - 01/2019
3	Fibrosis (Cirrhosis) 01/2020 - 03/2019
3	Brain Infarction 08/2016 - 06/2008
3	Sepsis (Septicemia) 08/2016 - 08/2006
3	Pulmonary Edema 08/2016 - 01/2012
3	Hypoxia (Hypoxemia) 04/2013 - 01/2010
2	Dysmenorrhea (Menstrual Pain) 05/2022 - 10/2020
2	Brain Injuries (Brain Injury) 01/2021 - 01/2021
2	Ischemic Stroke 01/2020 - 01/2017
2	Herpes Zoster 01/2020 - 01/2016
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2019 - 01/2017
2	Pain (Aches) 01/2019 - 01/2018
2	Leukemia 09/2017 - 09/2011
2	Anaphylaxis (Anaphylactic Shock) 09/2017 - 01/2017
2	Central Nervous System Diseases (CNS Diseases) 01/2017 - 01/2016
2	Stroke (Strokes) 05/2016 - 08/2013
2	Melanoma (Melanoma, Malignant) 07/2015 - 08/2012

Drug/Important Bio-Agent (IBA)

13	ruscogeninIBA 03/2022 - 07/2005
11	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2010
10	radix ophiopogonis drug combination radix ginseng fructus schizandrae (Shen Mai)IBA 01/2022 - 12/2015
8	Glucose (Dextrose)FDA LinkGeneric 03/2022 - 01/2016
8	Oxygen (Dioxygen)IBA 03/2022 - 01/2016
8	yi-qi-fu-maiIBA 01/2022 - 01/2016
8	SaponinsIBA 01/2020 - 12/2006
7	Pharmaceutical PreparationsIBA 05/2022 - 11/2010
7	Neuroprotective AgentsIBA 01/2022 - 10/2014
7	PowdersIBA 01/2020 - 01/2016
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2020 - 09/2005
6	Thromboplastin (Tissue Factor)IBA 02/2020 - 01/2010
5	blebbistatinIBA 01/2022 - 07/2015
5	LipopolysaccharidesIBA 02/2020 - 05/2008
4	ginsenoside Rb1IBA 03/2022 - 12/2015
4	Myosin Type IIIBA 01/2022 - 01/2017
4	Hematoxylin (Haematoxylon)IBA 01/2021 - 03/2019
4	Evans Blue (Blue, Evans)FDA Link 01/2021 - 06/2008
4	Eosine Yellowish-(YS) (Eosin)IBA 01/2021 - 03/2019
4	CarrageenanIBA 05/2008 - 07/2005
3	Therapeutic UsesIBA 01/2022 - 01/2020
3	schizandrinIBA 01/2021 - 12/2015
3	NF-kappa B (NF-kB)IBA 01/2021 - 06/2008
3	Myosin Heavy Chains (Myosin Heavy Chain)IBA 01/2021 - 07/2015
3	Biological ProductsIBA 01/2020 - 01/2012
3	Messenger RNA (mRNA)IBA 01/2018 - 01/2010
3	ophiopogonin DIBA 07/2015 - 07/2005
2	Oxytocin (Pitocin)FDA LinkGeneric 05/2022 - 01/2015
2	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 02/2016
2	TriterpenesIBA 01/2022 - 01/2020
2	CateninsIBA 01/2022 - 05/2019
2	AcidsIBA 10/2021 - 05/2016
2	Anti-Allergic Agents (Antiallergic Agents)IBA 10/2021 - 01/2020
2	Matrix Metalloproteinases (MMPs)IBA 01/2021 - 01/2020
2	triphenyltetrazoliumIBA 01/2021 - 01/2021
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 04/2020 - 12/2016
2	Creatine Kinase (Creatine Phosphokinase)IBA 04/2020 - 12/2016
2	CytokinesIBA 02/2020 - 08/2016
2	Interleukin-6 (Interleukin 6)IBA 03/2019 - 05/2013
2	CollagenIBA 03/2019 - 07/2002
2	Cadherins (E-Cadherin)IBA 03/2019 - 09/2011
2	corydalmineIBA 01/2019 - 01/2018
2	Dynamins (Dynamin)IBA 01/2019 - 01/2017
2	SolutionsIBA 11/2018 - 01/2017
2	Nonmuscle Myosin Type IIAIBA 11/2018 - 01/2016
2	Interleukin-8 (Interleukin 8)IBA 01/2018 - 06/2008
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018 - 05/2008
2	Hexosaminidases (Hexosaminidase)IBA 09/2017 - 01/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2016 - 04/2013
2	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 09/2011 - 12/2009
2	Xylenes (Xylene)IBA 05/2008 - 07/2005
2	Ethanol (Ethyl Alcohol)IBA 05/2008 - 09/2005
1	Isoleucine (L-Isoleucine)FDA Link 05/2022
1	Linoleic Acid (Linoleate)IBA 05/2022
1	Glycerophospholipids (Phosphoglycerides)IBA 05/2022
1	Leucine (L-Leucine)FDA Link 05/2022

Therapy/Procedure

15	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2022 - 08/2006
5	Ligation 01/2019 - 09/2005
5	Oral Administration 08/2016 - 09/2005
3	Drug Therapy (Chemotherapy) 01/2022 - 02/2016
3	Therapeutics 11/2018 - 01/2012
3	Intravenous Injections 08/2016 - 01/2012
2	Ischemic Postconditioning 12/2021 - 11/2016